Intravenous Fosfomycin: A Potential Good Partner for Cefiderocol. Clinical Experience and Considerations
Multidrug resistant Gram-negative bacteremia represents a therapeutic challenge clinicians have to deal with. This concern becomes more difficult when causing germs are represented by carbapenem resistant <i>Acinetobacter baumannii</i> or difficult-to-treat <i>Pseudomonas aeruginos...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Book |
| Published: |
MDPI AG,
2022-12-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Multidrug resistant Gram-negative bacteremia represents a therapeutic challenge clinicians have to deal with. This concern becomes more difficult when causing germs are represented by carbapenem resistant <i>Acinetobacter baumannii</i> or difficult-to-treat <i>Pseudomonas aeruginosa</i>. Few antibiotics are available against these cumbersome bacteria, although literature data are not conclusive, especially for <i>Acinetobacter</i>. Cefiderocol could represent a valid antibiotic choice, being a molecule with an innovative mechanism of action capable of overcoming common resistance pathways, whereas intravenous fosfomycin may be an appropriate partner either enhancing cefiderocol activity or avoiding resistance development. Here we report two patients with MDR Gram negative bacteremia who were successfully treated with a cefiderocol/fosfomycin combination. |
|---|---|
| Item Description: | 10.3390/antibiotics12010049 2079-6382 |